BioXcel Therapeutics Inc
BTAI
Get informed when a big investor buys or sells
+ FollowMarket Cap$36.13M
Close$
$-1.08
193.3% downside
Current Fair Value
193.3% downsideOvervalued by 193.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.13 Million |
|---|---|
| Enterprise Value | $119.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.73 |
| Beta | 0.31 |
| Outstanding Shares | 12,208,000 |
Return
| Return on Equity | 71.38% |
|---|---|
| Return on Assets | -221.41% |
| Return on Invested Capital | 299.79% |
Valuation & Multiples
| P/E Ratio | -0.19 |
|---|---|
| PEG | -0.25 |
| Price to Sales | - |
| Price to Book Ratio | -0.13 |
| Enterprise Value to Revenue | 175.35 |
| Enterprise Value to EBIT | -1.9 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.84 |
| Debt to Equity | -0.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$381,491
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$403,315
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 44.56%▲ 19.64% |
|---|---|
| Total Invested | $7.27M▲ 28.42% |
| Investors Holding | 39▼ 2.00% |
ESG Score
No data
About BioXcel Therapeutics Inc
CEO: Vimal Mehta